Editas Medicine, Inc. (EDIT): Price and Financial Metrics
EDIT Stock Summary
- The ratio of debt to operating expenses for Editas Medicine Inc is higher than it is for about merely 13.33% of US stocks.
- With a price/sales ratio of 29.3, Editas Medicine Inc has a higher such ratio than 92.05% of stocks in our set.
- Revenue growth over the past 12 months for Editas Medicine Inc comes in at 341.93%, a number that bests 98.09% of the US stocks we're tracking.
- Stocks that are quantitatively similar to EDIT, based on their financial statements, market capitalization, and price volatility, are SRPT, ALPN, STRO, SRRK, and SGMO.
- EDIT's SEC filings can be seen here. And to visit Editas Medicine Inc's official web site, go to www.editasmedicine.com.
EDIT Stock Price Chart Interactive Chart >
EDIT Price/Volume Stats
|Current price||$39.51||52-week high||$99.95|
|Prev. close||$39.46||52-week low||$21.41|
|Day high||$40.69||Avg. volume||2,485,791|
|50-day MA||$49.09||Dividend yield||N/A|
|200-day MA||$42.98||Market Cap||2.66B|
Editas Medicine, Inc. (EDIT) Company Bio
Editas Medicine Inc. operates as a genome editing company. It focuses on translating its genome editing technology into a class of human therapeutics that enable precise and corrective molecular modification to treat the underlying cause of a range of diseases at the genetic level. Editas Medicine Inc. was formerly known as Gengine, Inc. and changed its name to Editas Medicine Inc. in November 2013. The company was founded in 2013 and is based in Cambridge, Massachusetts.
EDIT Latest News Stream
|Loading, please wait...|
EDIT Latest Social Stream
View Full EDIT Social Stream
Latest EDIT News From Around the Web
Below are the latest news stories about Editas Medicine Inc that investors may wish to consider to help them evaluate EDIT as an investment opportunity.
A rare genetic disease that causes combined blindness and deafness may have a novel treatment in line after positive phase 1/2 trial results last month.
In this video from Motley Fool Live, recorded on March 15, Fool.com contributors Brian Orelli and Keith Speights discuss the difference between ex vivo gene editing (outside the body) and in vivo editing (within the patient). CRISPR Therapeutics (NASDAQ: CRSP) and its partner Vertex Pharmaceuticals (NASDAQ: VRTX) have mastered ex vivo gene editing, but the strategy is limited to diseases where cells can be manipulated outside the body. Up-and-coming gene editing companies may have a bigger opportunity if they can master the in vivo technique.
You've no doubt heard the investing adage to "buy the dip." But what if the dip is a really bad one? Sometimes buying stocks that fall significantly isn't such a great idea. On the other hand, there are other cases where scooping up shares when they've retreated a lot can pay off in a big way over the long run.
Editas (EDIT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Booming CAGR of 20.8%, CRISPR and CAS Gene Market to Surpass US$ 7,603.8 Million by 2027 | Caribou Biosciences Inc., CRISPR Therapeutics, Mirus Bio LLC, Editas Medicine, Takara Bio Inc
A new market study on the 2020-2027 CRISPR and CAS Gene Market with 100+ market data Tables, Pie Chat, Graphs & Figures spread through Pages and easy to understand detailed analysis. At present, the market is developing its presence. The Research report
EDIT Price Returns
Continue Researching EDITWant to do more research on Editas Medicine Inc's stock and its price? Try the links below:
Get Free Updates
Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!